Cutaneous manifestations of HIV Infection

Mucocutaneous Manifestations of Viral Diseases

Volumn , Issue , 2002, Pages 307-396

  Cockerell, Clay J ^a   Cohen, Philip R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882901395     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (178)

1. MS Gottlieb, R Schroff, HM Schanker, JD Weisman, PT Fan, RA Wolf, A Saxon. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305:1425-1431, 1981.
2. C Flexner. HIV—protease inhibitors. N Engl J Med 338: 1281-1291, 1998.
3. RM Gulick, JW Mellors, D Havlir, JJ Eron, C Gonzalez, D McMahon, D McMahon, DD Richman, FT Valentine, L Jonas, A Meibohm, EA Emini, JA Chodakewitz. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739, 1997.
4. B Autran, G Carcelain, TS Li, C Blanc, D Mathez, R Tubiana, C Katlama, P Debre, J Leibowitch. Positive effects of combined antiretroviral therapy on CD4 + T cell homeostasis and function in advanced HIV disease. Science 277:112-116, 1997.
5. S Staszewski, J Morales-Ramirez, KT Tashima, A Rachlis, D Skiest, J Stanford, R Stryker, P Johnson, DF Labriola, D Farina, DJ Manion, NM Ruiz. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341: 1865-1873, 1999.
6. F Palella, K Delaney, AC Moorman, MO Loveless, J Fuhrer, GA Satten, DJ Aschman, SD Holmberg. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860, 1998.
7. JH Condra, WA Schleif, OM Blahy, LJ Gabryelski, DJ Graham, JC Quintero, A Rhodes, HL Robbins, E Roth, M Shivaprakash, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374: 569-571, 1995.
8. D Finzi, M Hermankova, T Pierson, LM Carruth, C Buck, RE Chaisson, TC Quinn, K Chadwick, J Margolick, R Brookmeyer, J Gallant, M Markowitz, DD Ho, DD Rich-man, RF Siliciano. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300, 1997.
9. BM Coldiron, PR Bergstresser. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 125:357-361, 1988.
10. B Tindall, S Barker, B Donovan, T Barnes, J Roberts, C Kronenberg, J Gold, R Penny, D Cooper. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 148: 945-949, 1988.
11. S Safran, R Ashley, C Houlihan, PS Cusick, J Mills. Clinical and serologic features of herpes simplex virus infection in patients with AIDS. AIDS 5:1107-1110, 1991.
12. EC Klatt, D Shibata. Cytomegalovirus infection in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 112:540-544, 1988.
13. H Masur. Clinical implications of herpes virus infections in patients with AIDS. Am J Med 92:1S-2S, 1992.
14. WE Stamm, HH Hansfield, AM Rompalo, RL Ashley, PL Roberts, L Corey. The association between genital ulcerative disease and acquisition of HIV infection in homosexual men. JAMA 260:1429-1433, 1988.
15. J Lawrence. Perspective. Molecular interactions among herpes viruses and human immunodeficiency viruses. J Infect Dis 162:338-347, 1990.
16. GL Marks, PE Nolan, KS Erlich, MN Ellis. Mucocutaneous dissemination of acylovir-resistant herpes simplex virus in a patient with AIDS. Rev Infect Dis 11:474-476, 1989.
17. AE Friedman-Kien, FL LaFleur, EC Gendler, NP Hennessey, R Montagna, S Halbert, P Rubinstein, K Krasinski, E Zang, B Poiesz. Herpes zoster: a possible early clinical sign for development of acquired immunodeficiency syndrome in high-risk individuals. J Am Acad Dermatol 14: 1023-1028, 1986.
18. S Pahwa, K Biron, W Lim, P Swenson, MH Kaplan, N Sadick, R Pahwa. Continuous varicella zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 260:2879-2882, 1988.
19. IH Gilson, JH Barnett, MA Conant, OL Laskin, J Williams, PG Jones. Disseminated ecthymatous varicella-zoster virus infection in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 20:637-642, 1989.
20. PR Cohen, VP Beltranny, ME Grossman. Disseminated herpes zoster in patients with immunodeficiency virus infection. Am J Med 84:1076-1080, 1988.
21. MA Jacobson, TG Berger, S Fikrig, P Becherer, JW Moohr, SC Stanat, KK Biron. Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112:187-191, 1990.
22. KE Bowers. Cytomegalovirus infection. In: IM Freedberg, AZ Eisen, K Wolff, KF Autsten, LA Goldsmiths, SI Katz, TB Fitzpatrick, eds. Fitzpatrick’s Dermatology in General Medicine. McGraw-Hill NY, NY. Vol. 2, 5th ed, 1999, pp 2540-2457.
23. D Greenspan, JS Greenspan, G Overby, H Hollander, DI Abrams, L MacPhail, C Borowsky, DW Feigal Jr. Risk factors for rapid progression from hairy leukoplakia to AIDS: a nested case-control study. J Acquir Immune Defic Syndr 4:652-658, 1991.
24. KJ Smith, HG Skelton, P Angritt. Histopathologic features of HIV-associated skin disease. Dermatol Clin 9:551-578, 1991.
25. CJ Cockerell. Cutaneous manifestations of HIV infection. In: AE Friedman-Kien, CJ Cockerell, eds. Color Atlas of AIDS. Philadelphia: WB Saunders, 1989, p 96.
26. JM Palefsky, J Gonzales, RM Greenblatt, DK Ahn, H Hollander. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA 263:2911-2916, 1990.
27. MA Byrne, D Taylor-Robinson, PE Munday, JR Harris. The common occurrence of human papillomavirus in intraepithelial neoplasia in women infected by HIV. AIDS 3: 379-382, 1989.
28. JH Frazer, G Medley, RM Cratper. Association between anorectal dysplasia, human papillomavirus and immunodeficiency virus infection in homosexual men. Lancet 2: 657-660, 1986.
29. TG Berger, WS Sawchuk, C Leonardi, A Langenberg, J Tappero, PE Leboit. Epidermodysplasia verruciformis-as-sociated papillomavirus infection complicating human immunodeficiency virus disease. Br J Dermatol 126:79-83, 1991.
30. A McMillan, PE Bishop. Clinical course of anogenital warts in man infected with HIV. Genitourin Med 65: 225 -228, 1989.
31. RR Redfield, DC Wright, WD James, TS Jones, C Brown, DS Burke. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316:673-676, 1987.
32. TG Berger, I Greene. Bacterial, viral, fungal and parasitic infections in HIV disease and AIDS. Dermatol Clin 3: 465-492, 1991.
33. KJ Smith, HG Skelton, J Yeager, WD James, KF Wagner. Molluscum contagiosum. ultrastructure evidence for its presence in skin adjacent to clinical lesions in patients infected with human immunodeficiency virus type 1. Arch Dermatol 128:223-227, 1992.
34. CS Petersen, J Gerstoft. Molluscum contagiosum in patients with human immunodeficiency virus infection. Dermatology 184:19-21, 1992.
35. TJ Torok. Parvovirus and human disease. Adv Intern Med 37:431-455, 1992.
36. LA Ross, KS Kim, Z Comport. Successful treatment of disseminated measles in a patient with acquired immune deficiency syndrome: consideration of anti-viral and passive immunotherapy. Am J Med 88:313-314, 1990.
37. R Ganesh, D Castle, D Gibbon, I Phillips, C Bradbeer. Staphylococcal carriage in HIV infection. Lancet 2:558, 1989.
38. R Steinhart, AL Reingold, F Taylor, G Anderson, JD Wenger. Invasive Haemophilus influenzae infections in men with HIV infection. JAMA 268:3350-3352, 1992.
39. WL Strauss, SM Ostroff, DB Jernigan, TE Kiehn, EM Sordillo, D Armstrong, N Boone, N Schneider, JO Kilburn, VA Silcox, et al. Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients. Ann Intern Med 120: 118-125, 1994.
40. PK Rohatgi, JV Palazzolo, NB Saini. Acute miliary tuberculosis of the skin in acquired immunodeficiency syndrome. J Am Acad Dermatol 26:285-287, 1992.
41. TC Quinn, RO Cannon, D Glasser, SL Groseclose, WS Brathwaite, AS Fauci, EW Hook 3rd. The association of syphilis with risk of human immunodeficiency virus infection in patients attending sexually transmitted disease clinics. Arch Int Med 150:1297-1302, 1990.
42. K Adal, CJ Cockerell, WP Petrie. Cat scratch disease, bacillary angiomatosis, and other infections due to Rochali-maea. N Engl J Med 330:1509-1515, 1994.
43. F Janssen, A Zelinsky-Gurung, E Caumes, JM Decazed. Group A streptococcal cellulitis-adenitis in a patient with the acquired immunodeficiency syndrome. J Am Acad Dermatol 24:363-365, 1991.
44. LK Dropulic, JM Leslie, LJ Eldred, J Zenilman, CL Sears. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J Infect Dis 171:930-937, 1995.
45. LA Cone, DR Woodard, RG Byrd, K Schulz, SM Kopp, PM Schlievert. A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS. J Infect Dis 165:638-643, 1992.
46. K Javaly, HW Horowitz, GP Wormser. Nocardiosis in patients with human immunodeficiency virus infection. Medicine 71:128-138, 1992.
47. M Drancourt, E Bonnet, H Gallais, Y Peloux, D Raoult. Rhodococcus equi infection in patients with AIDS. J Infect 24:123-131, 1992.
48. B Halioua, O Patey, D Casciani, JP Emond, A Dublanchet, JE Malkin, C Lafaix. Cutaneous diphtheria in a patient with HIV infection. Ann Dermatol Venereol 119:874-877, 1992.
49. CJ Cockerell, PE LeBoit. Bacillary angiomatosis. A novel pseudoneoplastic, infectious vascular disorder. J Am Acad Dermatol 22:501-519, 1990.
50. N Gregory, M Sanchez, MR Buchness. The spectrum of syphilis in patients with human immunodeficiency virus infection. J Am Acad Dermatol 22:1061-1067, 1990.
51. IS Strongin, SA Kale, MK Raymond, RL Luskin, GW Weisberg, JJ Jacobs. An unusual presentation of gonococcal arthritis in an HIV-positive patient. Ann Rheum Dis 50:572-573, 1991.
52. RL Regnery, BE Anderson, JE Clarridge, MC Rodri-guez-Barradas, DC Jones, JH Carr. Characterization of a novel Rochalimaea species, R. henselae sp. nov. isolated from blood of a febrile, human immunodeficiency viruspositive patient. J Clin Microbiol 30:265-274, 1992.
53. JE Koehler, FD Quinn, TG Berger, PE LeBoit, Tappero JW. Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis. N Engl J Med 327:1625-1631, 1992.
54. MD Geman. Treatment of multidrug resistant tuberculosis. N Engl J Med 329:784-791, 1993.
55. SM Skinner, RL DeVillez. Sepsis associated with Norwegian scabies in patients with acquired immunodeficiency syndrome. Arch Dermatol 50:213-216, 1992.
56. NP Hennessey, EL Parro, CJ Cockerell. Cutaneous Pneumocystis carinii infection in patients with acquired immunodeficiency syndrome. Arch Dermatol 127:1699-1701, 1991.
57. C Postigo, R Llamas, C Zarco, R Rubio, F Pulido, JR Costa, L Iglesias. Cutaneous lesions in patients with visceral leishmaniasis and HIV infection. J Infect 35: 265-268, 1997.
58. E Leibovitz, M Rigaud, S Chandwani, A Kaul, MA Greco, H Pollack, R Lawrence, D Di John, B Hanna, K Krasinski, et al. Disseminated fungal infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J 10:888-894, 1991.
59. DG Fish, NM Ampel, JN Galgiani, CL Dols, PC Kelly, CH Johnson, D Pappagianis, JE Edwards, RB Wasserman, RJ Clark, et al. Coccidioidomycosis during human immunodeficiency virus infection: areview of 77 patients. Medicine 69:384-391, 1990.
60. P Manrique, J Mayo, JA Alvarez, X Ganchegui, I Zabalza, M Flores. Polymorphous cutaneous cryptococcosis: Nodular, herpes-like, and molluscum-like lesions in a patient with the acquired immunodeficiency syndrome. J Am Acad Dermatol 26:122-124, 1992.
61. PR Cohen, ME Grossman, DN Silvers. Disseminated histoplasmosis and human immunodeficiency virus infection. Int J Dermatol 30:614-622, 1991.
62. MB Chaker, CJ Cockerell. Concomitant psoriasis, seborrheic dermatitis and disseminated cutaneous histoplasmosis in a patient infected with human immunodeficiency virus. J Am Acad Dermatol 29:311-313, 1993.
63. MC Cole, PR Cohen, KH Satra, ME Grossman. The concurrent presence of systemic disease pathogens and cutaneous Kaposi’s sarcoma in the same lesion: Histoplasma capsulatum and Kaposi’s sarcoma coexisting in a single skin lesion in a patient with AIDS. J Am Acad Dermatol 26:285-287, 1992.
64. CL Terrell, CE Hughes. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 67:69-91, 1992.
65. J Romani, L Puig, E Baselga, JM De Moragas. Reiter’s syndrome-like pattern in AIDS-associated psoriasiform dermatitis. Int J Dermatol 35:484-488, 1996.
66. thed. New York: McGraw-Hill, 1999, p 2312.
67. T Meola, NA Soter, R Ostrecher, M Sanchez, JA Moy. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol 29:216-220, 1993.
68. AG Martin, CC Weaver, CJ Cockerell, TG Berger. Pityriasis rubra pilaris in the setting of HIV infection: clinical behaviour and association with explosive cystic acne. Br J Dermatol 126:617-620, 1992.
69. Le P Bozec, M Janier, P Reygagnee, L Pinquier, C Blanchet-Bardon, L Dubertret. Pityriasis rubra pilaris in a patient with AIDS. Acta Derm Venereol 118:862-864, 1991.
70. D Rosenthal, PE LeBoit, L Klumpp, TG Berger. Human immunodeficiency virus-associated eosinophilic folliculitis: a unique dermatitis associated with advanced human immunodeficiency virus infection. Arch Dermatol 127: 206-209, 1991.
71. NS Sadik, NS McNutt. Cutaneous hypersensitivity reactions in patients with AIDS. Int J Dermatol 32:621-627, 1993.
72. G Pantaleo, C Graziosi, AS Fauci. Immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328:327-335, 1993.
73. PE LeBoit, CJ Cockerell. Nodular lesions of erythema elevatum diutinum in patients with human immunodeficiency infection. J Am Acad Dermatol 28:919-922,1993.
74. N Tojo, N Yoshimura, M Yoshizawa, M Ichioka, M Chida, I Miyazato, S Taniai, F Marumo, O Matubara, T Kato, et al. Vitiligo and chronic photosensitivity in human immunodeficiency virus infection. Jpn J Med 30:255-259,1991.
75. MT Herranz, A el Amrani, P Aranegui, JF Jimenez-Alonso, JM Rodenas, RM Vivaldi. Porphyria cutanea tarda and acquired immunodeficiency syndrome: pathogenetic implications. Arch Dermatol 12:1585-1586, 1991.
76. BM Egbert, PE LeBoit, T McCalmont, CH Hu, C Austin. Caterpillar bodies: distinctive, basement membrane-containing structures in blisters of porphyria. Am J Dermato-pathol June, 15:199-202, 1993.
77. CJ Cockerell. Successful treatment of HIV-related porphyria cutanea tarda with low-dose oral hydroxychloroquine. Poster Presentation, American Academy of Dermatology, Washington, DC. 1996.
78. KE Anderson, DE Goeger, RW Carson, SM Lee, RB Stead. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Eng J Med 322:315-317, 1990.
79. SA Coopman, RA Johnson, R Platt, RS Stern. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 328:1670-1674, 1993.
80. DW Metry, CJ Lahart, KL Farmer, AA Hebert. StevensJohnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 44:354-357, 2001.
81. I Williams, IV Weller, A Malni, J Anderson, MF Waters. Thalidomide hypersensitivity in AIDS. Lancet 337: 436-437, 1991.
82. PJ Bayard, TG Berger, MA Jacobsen. Drug hypersensitivity reactions in human immunodeficiency virus disease. J Acquir Immune Defic Syndr 5:1237-1257, 1992.
83. PP Koopmans, AJ van der Ven, TB Vree, JW van der Meer. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: Allergic or toxic? AIDS 9: 217-222, 1995.
84. PC Don, F Fusco, P Fried, A Batterman, FP Duncanson, TH Lenox, NC Klein. Nail dyschromia associated with zidovudine. Ann Intern Med 112:145-146, 1990.
85. RG Greenberg, TG Berger. Nail and mucocutaneous hyperpigmentation with azidothymidine therapy. J Am Acad Dermatol 22:327-330, 1990.
86. F Bouscarat, C Bouchard. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir. N Engl J Med 338:1776-1777, 1998.
87. M Alam, RK Scher. Indinavir-related recurrent paronychia and ingrown toenails. Cutis 64:277-278, 1999.
88. F Bouscarat, MH Prevot, S Matheron. Alopecia associated with indinavir therapy. N Engl J Med 341:618, 1999.
89. A Darvay, K Acland, W Lynn, R Russell-Jones. Striae formation in two HIV-positive persons receiving protease inhibitors. J Am Acad Dermatol 41:467-469, 1999.
90. M Silva, PR Skolnik, SL Gorbach, Spiegelman D, IB Wilson, MG Fernandez-DiFranco, TA Knox. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12:1645-1651, 1998.
91. K Williamson, AC Reboli, SM Manders. Protease inhibitor-induced lipodystrophy. J Am Acad Dermatol 40: 635-636, 1999.
92. JC Lo, K Mulligan, VW Tai, H Algren, M Schambelan. Buffalo hump in men with HIV-1 infection. Lancet 351:867-870, 1998.
93. R Striker, D Conlin, M Marz, L Wiviott. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 27: 218-220, 1998.
94. A Carr, DA Cooper. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 339:1296, 1998.
95. DM Aboulafia, D Bundow. Images in clinical medicine. Buffalo hump in a patient with the acquired immunodeficiency syndrome. N Engl J Med 339:1297, 1998.
96. VR Roth, S Kravcik, JB Angel. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 27:65-67, 1998.
97. I Herry, L Bernard, P de Truchis, C Perronne. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 25:937-938, 1997.
98. MS Hirsch, A Klibanski. Editorial response: What price progress? Pseudo-Cushing’s syndrome associated with antiretroviral therapy in patients with human immunodeficiency virus infection. Clin Infect Dis 27:73-75, 1998.
99. JW van der Pijl, PH Frissen, P Reiss, HJ Hulsebosch, JG Van Den Tweel, JM Lange, SA Danner. Foscarnet and penile ulceration. Lancet 335:286, 1990.
100. C Blanshard. Generalized cutaneous rash associated with foscarnet usage in AIDS. J Infect Dis 23:336-337, 1991.
101. MH Kaplan, NS Sadik, M Talmor. Acquired trichomegaly of the eyelashes—a cutaneous marker of acquired immunodeficiency syndrome. J Am Acad Dermatol 25: 801-804, 1991.
102. NS Sadick. Clinical and laboratory evaluation of AIDS trichopathy. Int J Dermatol 32:33-38, 1993.
103. CJ Cockerell, ET Dolan. Widespread cutaneous and systemic calcification (calciphylaxis) in patients with the acquired immunodeficiency syndrome and renal disease. J Am Acad Dermatol 26:559-562, 1992.
104. CJ Cockerell. Noninfectious inflammatory skin diseases in HIV infected individuals. Dermatol Clin 9:531-541, 1991.
105. AA Fisher. Condom conundrums. Cutis 48:359-360, 1991.
106. M Reichel, TM Mauro, VA Ziboh, AC Huntley, MP Fletcher. Acrodermatitis enteropathica in a patient with the acquired immunodeficiency syndrome. Arch Dermatol 128:415-417, 1992.
107. Schulz TF, CH Boshoff, RA Weiss. HIV infection and neoplasia. Lancet 348:587-591, 1996.
108. D Caussy, JJ Goedert, J Palefsky, J Gonzales, CS Rabkin, RA DiGioia, WC Sanchez, RJ Grossman, G Colclough, SZ Wiktor, et al. Interaction of HIV and papillomaviruses: association with anal intraepithelial abnormality in homosexual men. Int J Cancer 46:214-219, 1990.
109. KJ Smith, HG Skelton, J Yeager, P Angritt, KF Wagner. Cutaneous neoplasms in a military population of HIV-1positive patients. J Am Acad Dermatol 29:400-406,1993.
110. ME Hagensee, N Kiviat, CW Critchlow, SE Hawes, J Kuypers, S Holte, DA Galloway. Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis 176:625-631, 1997.
111. T Nagatani, M Miyazawa, T Matsuki. Adult T-cell leukemia/lymphoma (ATL)—clinical, histopathological, immunological and immunohistochemical characteristics. Exp Dermatol 1:248-252, 1992.
112. AE Friedman-Kien, BR Saltzman. Clinical manifestations of classical endemic African and epidemic AIDS-associated Kaposi’s sarcoma. J Am Acad Dermatol 22: 1237-1250, 1990.
113. AE Friedman-Kien, BR Saltzman, YZ Cao, MS Nestor, M Mirabile, JJ Li, TA Peterman. Kaposi’s sarcoma in HIVnegative homosexual men. Lancet 335:168-169, 1990.
114. V Beral, TA Peterman, RL Berkelman, HW Jaffe. Kaposi’s sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 335:123-128, 1990.
115. Y Chang, E Cesarman, MS Pessin, F Lee, J Culpepper, DM Knowles, PS Moore. Identification of herpesvirus DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:1865-1869, 1994.
116. SF Krown, JWM Golft, D Niedzwicki. Interferon and zidovudine—safety tolerance and clinical and virological effects in patients with Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112:812-821, 1990.
117. S Walmsely, DW Northfelt, B Melosky, M Conant, AE Friedman-Kien, B Wagner. Treatment of AIDS-related cutaneous Kaposi’s sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr 22: 235-246, 1999.
118. SJ Orlow, H Kamino, RL Lawrence. Multiple subcutaneous leiomyosarcomas in an adolescent with AIDS. Am J Pediatr Hematol Oncol 14:265-268, 1992.
119. United States Department of Health and Human Services, Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents; February 5, 2001, available on the HIV/AIDS Treatment Information Service Website (http://www.hivatis.org).
120. PA Volberding, SW Lagakos, MA Koch, C Pettinelli, MW Myers, DK Booth, HH Balfour Jr., RC Reichman, JA Bar-lett, MS Hirsch, et al. Zidovudine in asymptomatic HIV infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. The AIDS Clinical Trial Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 332:941-949, 1990.
121. DD Richman. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 37:1207-1213, 1993.
122. RS Hogg, KV Heath, B Yip, KJ Craib, MV O’Shaugh-nessy, MT Schechter, JS Montaner. Improved survival among HIV infected individuals following initiation of antiretroviral therapy. JAMA 279:450-454, 1998.
123. BP Griffith, H Brett-Smith, G Kim, JW Mellors, TM Chacko, RB Garner, YC Cheng, P Alcabes, G Friedland. Effect of stavudine on HIV-1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociation antigenemia. J Infect Dis 173:1252-1255, 1996.
124. JO Kahn, SW Lagakos, DD Richman, A Cross, C Pettinelli, SH Liou, M Brown, PA Volberding, CS Crumpacker, G Beall, et al. A controlled trial comparing continued zidovudine with didanosine in HIV infection. The NIAID AIDS Clinical Trial Group. N Engl J Med 327:581-587, 1992.
125. SM Plauge, SS Good, WH Miller. Abacavir (1592), a second generation nucleoside HIV reverse transcriptase inhibitor. Int Antiviral News 6:7, 1998.
126. th International Conference on Retroviruses and Opportunistic Infections; Chicago, Illinois, January 31-Feb-ruary 4, 1999. Abstract no. 19, p. 70.
127. SJ Smerdon, J Jager, J Wang, LA Kohlstaedt, AJ Chirino, JM Friedman, PA Rice, TA Steitz. Structure of the binding site for the non-nucleoside inhibitors of the reverse transcriptase of HIV-1. Proc Natl Acad Sci USA 26: 3911-3915, 1994.
128. D Havlir, SH Cheesman, M McLaughlin, R Murphy, A Erice, SA Spector, TC Greenough, JL Sullivan, D Hall, M Myers et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with HIV infection. J Infect Dis 171:537-545, 1995.
129. JH Nunberg, WA Schleif, EJ Boots, JA O’Brien, JC Quintero, JM Hoffman, EA Emini, ME Goldman. Viral resistance to HIV-1: Specific pyridinone reverse transcriptase inhibitors. J Virol 65:4887-4892, 1991.
130. D Richman, D Havlir, J Corbeil, D Looney, C Ignacio, SA Spector, J Sullivan, S Cheeseman, K Barringer, D Pauletti, et al. Nevirapine resistance mutations of HIV-1 selected during therapy. J Virol 68:1660-1666, 1994.
131. A Bamer, M Myers. Nevirapine and rashes. Lancet 351: 1133, 1998.
132. RT D’Aquila, MD Hughes, VA Johnston, MA Fischl, JP Sommadossi, SH Liou, J Timpone, M Myers, N Basgoz, M Niu, MS Hirsch. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized double blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trial Group Protocol 241 Investigators. Ann Intern Med 124:1019-1030, 1996.
133. DV Havlir, JMA Lange. New antiretrovirals and new combinations. AIDS 12(suppl A):S165-S174, 1998.
134. PC Bellman. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed. AIDS 12:1333-1340, 1998.
135. R Murphy. Non-nucleoside reverse transcriptase inhibitors. AIDS Clin Care 9:75-79, 1997.
136. JSG Montaner, V Montessori, R Harrigan, M O’Shaugh-nessy, R Hogg. Antiretroviral therapy: the state of the art. Biomed Pharmacother 53:63-72, 1999.
137. SG Deeks, M Smith, M Holodnity, JO Khan. HIV-1 protease inhibitors. A review for clinicians. JAMA 277: 145-153, 1997.
138. CK Mc Donald, DR Kurtzkes. HIV-1 protease inhibitors. Arch Intern Med 157:951-959, 1997.
139. C Debouck. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Human Retroviruses 8:153-164, 1992.
140. JC Schmit, B Weber. Recent advances in antiretroviral therapy and HIV infection monitoring. Intervirology 40: 304-321, 1997.
141. M Markowitz, M Saag, WG Powderly, AM Hurley, A Hsu, JM Valdes, D Henry, F Sattler, A La Marca, JM Leonard, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 333:1534-1539, 1995.
142. MN Chaudry, DH Shepp. Antiretroviral agents: current usage. Dermatol Clin 15:319-329, 1997.
143. M Silva, PR Skolnik, SL Gorbach, D Spiegelman, IB Wilson, MG Fernandez-DiFranco, TA Knox. The effect of protease inhibitors on weight and body composition in HIV infected patients. AIDS 12:1645-1651, 1998.
144. A Carr, DA Cooper. Images in clinical medicine. Lipodystrophy associated with an HIV protease inhibitor. N Engl J Med 339:1296, 1998.
145. DM Aboulafia, D Bundaw. Images in clinical medicine. Buffalo hump in a patient with HIV. N Engl J Med 339:1297, 1998.
146. K Williamson, AC Reboli, SM Manders. Protease inhibitor-induced lipodystrophy. JAAD 40:635-636, 1999.
147. JH Condra, WA Schleif, OM Blahy, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571, 1995.
148. RT Mitsuyasu, PR Skolnik, SR Cohen, B Conway, MJ Gill, PC Jensen, JJ Pulvirenti, LN Slater, RT Schooley, MA Thompson, RA Torres, CM Tsoukas. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV 15355 Study Team AIDS 12:F103-F109, 1998.
149. DW Cameron, M Heath-Chiozzi, S Danner, C Cohen, S Kravcik, C Maurath, E Sun, D Henry, R Rode, A Potthoff, J Leonard. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351:543-549, 1998.
150. H Nielsen. Hypermennorrhea associated with ritonavir [letter]. Lancet 353:811-812, 1999.
151. LJ Martinez. Approval of new protease inhibitors. Res Init Treat Act 2:1-3, 1996.
152. K Boubaker, P Sudre, F Bally, G Vogel, JY Meuwly, MP Glauser, A Telenti. Changes in renal function associated with indinavir. AIDS 12:F249-F254, 1998.
153. H Hanabusa, H Tagami, H Hataya. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med 340:392-393, 1999.
154. th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28-October 1, 1997.
155. American Society for Microbiology’s 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 26-29, 1999.
156. IS Fortgang, PC Belitsos, RE Chaisson, RD Moore. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 90:1443-1436, 1995.
157. HJ Hofstede, S de Marie, NA Foudraine, SA Danner, K Brinkman. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 11:611-616, 2000.
158. Lonergan JT, Behling C, Pfander H, TI Hassanein, WC Mathews. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 31:162-166, 2000.
159. R Chodock, E Mylonakis, D Shemin, V Runarsdottir, P Yodice, R Renzi, K Tashima, C Towe, JD Rich. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis: the role of hemodialysis treatment. Nephrol Dial Transplant 14:2484-2486, 1999.
160. K Mulligan, C Grunfeld, VW Tai, H Algren, M Pang, DN Chernoff, JC Lo, M Schambelan. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23:35-43, 2000.
161. G Behrens, A Dejam, H Schmidt, HJ Balks, G Brabant, T Korner, M Stoll, RE Schmidt. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63-F70, 1999.
162. CM Shikuma, C Waslien, J Mc Keague, N Baker, M Arakaki, XW Cui, S Souza, A Imrie, R Arakaki. Fasting hyper-insulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 13:1359-1365, 1999.
163. KD Miller, E Jones, JA Yanovski, R Shankar, I Feuerstein, J Falloon. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871-875, 1998.
164. JC Lo, K Mulligan, VW Tai, H Algren, M Schambelan. Buffalo hump in men with HIV-1 infection. Lancet 351:867-870, 1998.
165. A Carr, K Samaras, A Thorisdottir, GR Kaufmann, DJ Chisholm, DA Cooper. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidemia and diabetes mellitus: a cohort study. Lancet 353:2093-2099, 1999.
166. T Saint-Marc, M Partisani, I Poizot-Martin, F Bruno, O Rouviere, JM Lang, JA Gastaut, JL Touraine. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13: 1659-1667, 1999.
167. A Carr, J Miller, M Law, DA Cooper. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14:F25-F32, 2000.
168. Martinez E, Conget I, Lozano L, R Casamitjana, JM Gatell. Reversion of metabolic abnormalities after switching from HIV-1 positive protease inhibitor to nevirapine. AIDS 13: 805-810, 1999.
169. P Barreiro, V Soriano, F Blanco, C Casimiro, JJ de la Cruz, J Gonzalez-Lahoz. Risk and benefits of replacing protease inhibitors by nevirapine in HIV-1 infected subjects under long-term successful triple combination therapy. AIDS 14:807-812, 2000.
170. R Roubenoff, L Weiss, A Mc Dermott, T Heflin, GJ Cloutier, M Wood, S Gorbach. A pilot study of exercise training to reduce trunk fat in adults with HIV-1 associated fat redistribution. AIDS 13:1373-1375, 1999.
171. A Carr, K Samaras, DJ Chisholm, DA Cooper. Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 351:1881-1883, 1998.
172. D Klein, L Hurley, S Sidney. Do protease inhibitors increase the risk of coronary heart disease among HIV-positive patients? Additional follow-up. Seventh Conference on Retroviruses and Opportunistic Infections (Abstract 33), San Francisco, CA, 2000.
173. JA Rascoosin, CM Kessler. Bleeding episodes in HIVpositive patients taking HIV protease inhibitors: A case series. Hemophilia 5:266-269, 1999.
174. SG Deeks, A Collier, J Lalezari, A Pavia, D Rodrigue, WL Drew, J Toole, HS Jaffe, AS Mulato, PD Lamy, W Li, JM Cherrington, N Hellmann, J Kahn. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV infected adults: a randomized double blind, placebo-controlled trial. J Infect Dis 176:1517-1523, 1997.
175. K Squires. Once-a-day protease inhibitor appears safe and effective after 48 weeks. Eighth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2001.
176. D Hazuda, CU Blau, P Felock, J Hastings, B Pramanik, A Wolfe, F Bushman, C Farnet, M Goetz, M Williams, K Silverman, R Lingham, S Singh. Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites. Antivir Chem Chemo-ther 10:63-70, 1999.
177. JM Kilby, S Hopkins, TM Venetta, B DiMassimo, GA Cloud, JY Lee, L Alldredge, E Hunter, D Lambert, D Bolognesi, T Matthews, MR Johnson, MA Nowak, GM Shaw, MS Saag. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp-41 mediated virus entry. Nat Med 4:1302-1307, 1998.
178. OT Rutschmann, M Opravil, A Iten, R Malinverni, PL Vernazza, HC Bucher, E Bernasconi, P Sudre, D Leduc, S Yerly, LH Perrin, B Hirschel. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort study. AIDS 12:F71-F77, 1998.